Использование нестероидных противовоспалительных препаратов в реальной клинической практике: новые возможности

2. Makris UE, Abrams RC, Gurland B, Reid MC. Management of persistent pain in the older patient: a clinical review. JAMA 2014; 312 (8): 825–36. DOI: 10.1001/jama.2014.9405
3. Hunter TS, Robison C, Gerbino PP. Emerging evidence in NSAID pharmacology: important considerations for product selection. Am J Manag Care 2015; 21 (Suppl. 7): S139–47.
4. Xu S, Rouzer CA, Marnett LJ. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life 2014; 66 (12): 803–11. DOI: 10.1002/iub.1334
5. Díaz-González F, Sánchez-Madrid F. NSAIDs: learning new tricks from old drugs. Eur J Immunol 2015; 45 (3): 679–86. DOI: 10.1002/eji.201445222
6. Vecchio AJ, Malkowski MG. The structural basis of endocannabinoid oxygenation by cyclooxygenase-2. J Biol Chem 2011; 286 (23): 20736–45. DOI: 10.1074/jbc.M111.230367
7. Vecchio AJ, Simmons DM, Malkowski MG. Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem 2010; 285 (29): 22152–63. DOI: 10.1074/jbc.M110.119867
8. Nilsen OG. Clinical pharmacokinetics of tenoxicam. Clin Pharmacokinet 1994; 26 (1): 16–43.
9. https://www.drugs.com/international/tenoxicam.html
10. http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/1....
11. Lora M, Morisset S, Ménard HA et al. Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin and aspirin. Prostaglandins Leukot Essent Fatty Acids 1997; 56 (5): 361–7.
12. Van Antwerpen P, Nève J. In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide families. Eur J Pharmacol 2004; 496 (1–3): 55–61.
13. Ferrari GV, Natera J, Paulina Montaña M. Scavenging of photogenerated ROS by Oxicams. Possible biological and environmental implications. J Photochem Photobiol B 2015; 153: 233–9. DOI: 10.1016/j.jphotobiol.2015.09.024
14. Ozgocmen S, Ardicoglu O, Erdogan H et al. In vivo effect of celecoxib and tenoxicam on oxidant/anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci 2005; 35 (2): 137–43.
15. Simpson J, Golding DN, Freeman AM et al. A large multicentre, parallel group, double-blind study comparing tenoxicam and piroxicam in the treatment of osteoarthritis and rheumatoid arthritis. Br J Clin Pract 1989; 43 (9): 328–33.
16. Moser U, Waldburger H, Schwarz HA, Gobelet CA. A double-blindrandomisedmulticentre study with tenoxicam, piroxicam and diclofenac sodium retard in the treatment of ambulant patients with osteoarthritis and extra-articular rheumatism. Scand J Rheumatol Suppl 1989; 80: 71–80.
17. Ejstrup L, Knudsen JV, Petersen L. A randomised double-blind multicentre trial comparing tenoxicam and ketoprofen in osteoarthritis. Scand J Rheumatol Suppl 1989; 80: 48–53.
18. Bellamy N, Buchanan WW, Chalmers A et al. A multicenter study of tenoxicam and diclofenac in patients with osteoarthritis of the knee. J Rheumatol 1993; 20 (6): 999–1004.
19. Riedemann PJ, Bersinic S, Cuddy LJ et al. A study to determine the efficacy and safety of tenoxicam versus piroxicam, diclofenac and indomethacin in patients with osteoarthritis: a meta-analysis. J Rheumatol 1993; 20 (12): 2095–103.
20. Langdon CG, Moran DG, Jamieson V et al. A multicentre study of tenoxicam for the treatment of osteo-arthritis and rheumatoid arthritis in general practice. J Int Med Res 1990; 18 (6): 489–96.
21. Kraag GR, Gordon DA, Ménard HA et al. Patient compliance with tenoxicam in family practice. Clin Ther 1994; 16 (3): 581–93.
22. Marcolongo R, Fioravanti A. Clinical experiences with tenoxicam. Preliminary results of a multicenter study. Recent Prog Med 1991; 82 (4): 242–9.
23. Ibrahima K, Kodjo G, Issa S et al. Clinical efficacy and tolerability of tenoxicam in African patients with osteoarthritis, rheumatoid arthritis, tendinitis and/or bursitis: an open study. Curr Med Res Opin 1991; 12 (7): 471–8.
24. Nived O, Sturfelt G, Eckernäs SA, Singer P. A comparison of 6 months' compliance of patients with rheumatoid arthritis treated with tenoxicam and naproxen. Use of patient computer data to assess response to treatment. J Rheumatol 1994; 21 (8): 1537–41.
25. Lund B, Andersen RB, Fossgreen J et al. A long-term randomised trial on tenoxicam and piroxicam in osteoarthritis of the hip or knee: a 24-month interim report focusing on the 12–24 month interval. Eur J Rheumatol Inflamm 1987; 9 (2): 58–67.
26. Lalos J, Tsachalos P, Gallis L. Long-term (four year) clinical trial with tenoxicam and basis therapy in patients suffering from rheumatoid arthritis. Scand J Rheumatol Suppl 1989; 80: 67–70.
27. Perez-Ruiz F, Alonso-Ruiz A, Ansoleaga JJ. Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. Clin Rheumatol 1996; 15 (5): 473–7.
28. Villa Alcázar LF, de Buergo M, Rico Lenza H, Montull Fruitós E. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. J Rheumatol 1996; 23 (7): 1194–9.
29. Valdés EF. Use of tenoxicam in patients with acute gouty arthritis. Eur J Rheumatol Inflamm 1987; 9 (2): 133–6.
30. Waterworth RF, Waterworth SM. An open assessment of tenoxicam (Tilcotil) in the treatment of acute gout in general practice. N Z Med J 1987; 100 (837): 744–5.
31. Van Durme CM, Wechalekar MD, Buchbinder R et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 2014; 9: CD010120. DOI: 10.1002/14651858.CD010120.pub2
32. Szpalski M, Hayez JP. Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain. A double-blind placebo-controlled study. Br J Rheumatol 1994; 33 (1): 74–8.
33. Cheung LK, Rodrigo C. Tenoxicam for pain relief following third molar surgery. Anesth Pain Control Dent 1992; 1 (4): 229–33.
34. Zacharias M, De Silva RK, Herbison P, Templer P. A randomized crossover trial of tenoxicam compared with rofecoxib for postoperative dental pain control. Anaesth Intensive Care 2004; 32 (6): 770–4.
35. Arslan H, Topcuoglu HS, Aladag H. Effectiveness of tenoxicam and ibuprofen for pain prevention following endodontic therapy in comparison to placebo: a randomized double-blind clinical trial. J Oral Sci 2011; 53 (2): 157–61.
36. Ilhan O, Agacayak KS, Gulsun B et al. A comparison of the effects of methylprednisolone and tenoxicam on pain, edema, and trismus after impacted lower third molar extraction. Med Sci Monit 2014; 20: 147–52. DOI: 10.12659/MSM.890239
37. Merry AF, Swinburn PF, Middleton NG et al. Tenoxicam and paracetamol-codeine combination after oral surgery: a prospective, randomized, double-blind, placebo-controlled study. Br J Anaesth 1998; 81 (6): 875–80.
38. Roelofse JA, Van der Bijl P, Joubert JJ. Analgesic and anti-inflammatory efficacy of tenoxicam and diclofenac sodium after third molar surgery. Anesth Prog 1996; 43 (4): 103–7.
39. Çebi AT, Kasapoğlu MB, Eren S, Kasapoğlu Ç. Comparison of the effects of diclofenac potassium and tenoxicam on postoperative pain, swelling, and trismus following third molar surgery. Turk J Med Sci 2018; 48 (2): 271–8. DOI: 10.3906/sag-1702-100
40. Kaplan V, Eroğlu CN. Comparison of the Effects of Daily Single-Dose Use of Flurbiprofen, Diclofenac Sodium, and Tenoxicam on Postoperative Pain, Swelling, and Trismus: A Randomized Double-Blind Study. J Oral Maxillofac Surg 2016; 74 (10): 1946.e1–6. DOI: 10.1016/j.joms.2016.05.015
41. Cevik E, Cinar O, Salman N et al. Comparing the efficacy of intravenous tenoxicam, lornoxicam, and dexketoprofen trometamol for the treatment of renal colic. Am J Emerg Med 2012; 30 (8): 1486–90. DOI: 10.1016/j.ajem.2011.12.010
42. Kekeç Z, Yilmaz U, Sözüer E. The effectiveness of tenoxicam vs isosorbide dinitrate plus tenoxicam in the treatment of acute renal colic. BJU Int 2000; 85 (7): 783–5.
43. Al-Waili NS, Saloom KY. Intravenous tenoxicam to treat acute renal colic: comparison with buscopancompositum. J Pak Med Assoc 1998; 48 (12): 370–2.
44. Al-Waili NS. Intramuscular tenoxicam to treat acute renal colic. Br J Urol 1996; 77 (1): 15–6.
45. Masudi T, Capitelli-McMahon H, Anwar S. Acute pain management in symptomatic cholelithiasis. World J Gastrointest Surg 2016; 8 (10): 713–8.
46. Chang WK, Wu HL, Yang CS et al. Effect on pain relief and inflammatory response following addition of tenoxicam to intravenous patient-controlled morphine analgesia: a double-blind, randomized, controlled study in patients undergoing spine fusion surgery. Pain Med 2013; 14 (5): 736–48. DOI: 10.1111/pme.12067
47. Gunusen I, Karaman S, Acar A et al. The efficacy of paracetamol versus tenoxicam on postoperative pain and morphine consumption after abdominal hysterectomy: a placebo-controlled, randomized study. Clin Exp Obstet Gynecol 2012; 39 (1): 49–52.
48. Munro FJ, Young SJ, Broome IJ et al. Intravenous tenoxicam for analgesia following laparoscopic cholecystectomy. Anaesth Intensive Care 1998; 26 (1): 56–60.
49. Akca T, Colak T, Kanik A et al. The effect of preoperative intravenous use of tenoxicam: a prospective, double-blind, placebo-controlled study. J Invest Surg 2004; 17 (6): 333–8.
50. Merry AF, Sidebotham DA, Middleton NG et al. Tenoxicam 20 mg or 40 mg after thoracotomy: a prospective, randomized, double-blind, placebo-controlled study. Anaesth Intensive Care 2002; 30 (2): 160–6.
51. Papathanassiou NP. Intra-articular use of tenoxicam in degenerative osteoarthritis of the knee joint. J Int Med Res 1994; 22 (6): 332–7.
52. Unlu Z, Ay K, Tuzun C. Comparison of intra-articular tenoxicam and oral tenoxicam for pain and physical functioning in osteoarthritis of the knee. Clin Rheumatol 2006; 25 (1): 54–61.
53. Erbas M, Simsek T, Kiraz HA et al. Comparison of the effectivity of oral and intra-articular administration of tenoxicam in patients with knee osteoarthritis. Braz J Anesthesiol 2015; 65 (5): 333–7. DOI: 10.1016/j.bjane.2013.12.003
54. Çift H, Özkan FÜ, Tolu S et al. Comparison of subacromial tenoxicam and steroid injections in the treatment of impingement syndrome. Eklem Hastalik Cerrahisi 2015; 26 (1): 16–20. DOI: 10.5606/ehc.2015.05
55. Guner S, Onder H, Guner SI et al. Effectiveness of local tenoxicam versus corticosteroid injection for plantar fasciitis treatment. Orthopedics 2013; 36 (10): e1322–6. DOI: 10.3928/01477447-20130920-27
56. Cook TM, Tuckey JP, Nolan JP. Analgesia after day-case knee arthroscopy: double-blind study of intra-articular tenoxicam, intra-articular bupivacaine and placebo. Br J Anaesth 1997; 78 (2): 163–8.
57. Talu GK, Ozyalçin S, Koltka K et al. Comparison of efficacy of intraarticular application of tenoxicam, bupivacaine and tenoxicam: bupivacaine combination in arthroscopic knee surgery. Knee Surg Sports Traumatol Arthrosc 2002; 10 (6): 355–60.
58. Oral EG, Hanci A, Ulufer Sivrikaya G et al. The Analgesic Effects of Morphine and Tramadol Added to Intra-articular Levobupivacaine-Tenoxicam Combination for Arthroscopic Knee Surgery on Postoperative Pain; a Randomized Clinical Trial. Anesth Pain Med 2015; 5 (3): e24047. DOI: 10.5812/aapm.5(3)2015.24047
59. Jawish R, Najdi H, Abi Safi C, Chameseddine A. The effect of intra-articular Tenoxicam on knee effusion after arthroscopy. Int Orthop 2015; 39 (7): 1423–6. DOI: 10.1007/s00264-014-2640-3
60. Sanel S, Arpaz O, Unay K et al. Comparison of intra-articular bupivacaine-morphine with bupivacaine-tenoxicam combinations on post-operative analgesia in patients with arthroscopic meniscectomy: a prospective, randomised study. Int Orthop 2016; 40 (3): 601–5. DOI: 10.1007/s00264-015-2990-5
61. Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35 (12): 1127–46. DOI: 10.2165/11633470-000000000-00000
62. Müller P, Dammann HG, Marinis E, Simon B. Gastroduodenal tolerance of tenoxicam versus diclofenac-Na: an endoscopy double-blind controlled study in healthy probands. Z Rheumatol 1989; 48 (5): 243–5.
63. Al-Quorain AA, Satti MB, Marwah S et al. Non-steroidal anti-inflammatory drug-induced gastropathy: a comparative endoscopic and histopathological evaluation of the effects of tenoxicam and diclofenac. J Int Med Res 1993; 21 (2): 89–97.
64. Perpignano G, Bogliolo A, Puccetti L. Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee. Int J Clin Pharmacol Res 1994; 14 (5–6): 203–16.
65. Lapeyre-Mestre M, Grolleau S, Montastruc JL. Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002–2006. Fundam Clin Pharmacol 2013; 27 (2): 223–30. DOI: 10.1111/j.1472-8206.2011.00991.x
66. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296 (13): 1633–44.
67. Varas-Lorenzo С, Riera-Guardia N, Calingaert B et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiology Drug Safety 2013; 22: 559–70.
68. Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology 2015; 23 (1): 1–16.
69. Arfè A, Scotti L, Varas-Lorenzo C et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016; 354: i4857. DOI: 10.1136/bmj.i4857
70. Каратеев А.Е. Теноксикам. Клин. фармакология и терапия. 2017; 26 (5): 44–50. / Karateev A.E. Tenoksikam. Klin. farmakologiia i terapiia. 2017; 26 (5): 44–50. [in Russian]

________________________________________________

1. Karateev A.E., Nasonov E.L., Ivashkin V.T. i dr. Ratsional'noe ispol'zovanie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii. Nauchno-prakticheskaia revmatologiia. 2018; 56: 1–29. https://doi.org/10.14412/1995-4484-2018-1-29 [in Russian]
2. Makris UE, Abrams RC, Gurland B, Reid MC. Management of persistent pain in the older patient: a clinical review. JAMA 2014; 312 (8): 825–36. DOI: 10.1001/jama.2014.9405
3. Hunter TS, Robison C, Gerbino PP. Emerging evidence in NSAID pharmacology: important considerations for product selection. Am J Manag Care 2015; 21 (Suppl. 7): S139–47.
4. Xu S, Rouzer CA, Marnett LJ. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life 2014; 66 (12): 803–11. DOI: 10.1002/iub.1334
5. Díaz-González F, Sánchez-Madrid F. NSAIDs: learning new tricks from old drugs. Eur J Immunol 2015; 45 (3): 679–86. DOI: 10.1002/eji.201445222
6. Vecchio AJ, Malkowski MG. The structural basis of endocannabinoid oxygenation by cyclooxygenase-2. J Biol Chem 2011; 286 (23): 20736–45. DOI: 10.1074/jbc.M111.230367
7. Vecchio AJ, Simmons DM, Malkowski MG. Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem 2010; 285 (29): 22152–63. DOI: 10.1074/jbc.M110.119867
8. Nilsen OG. Clinical pharmacokinetics of tenoxicam. Clin Pharmacokinet 1994; 26 (1): 16–43.
9. https://www.drugs.com/international/tenoxicam.html
10. http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/1....
11. Lora M, Morisset S, Ménard HA et al. Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin and aspirin. Prostaglandins Leukot Essent Fatty Acids 1997; 56 (5): 361–7.
12. Van Antwerpen P, Nève J. In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide families. Eur J Pharmacol 2004; 496 (1–3): 55–61.
13. Ferrari GV, Natera J, Paulina Montaña M. Scavenging of photogenerated ROS by Oxicams. Possible biological and environmental implications. J Photochem Photobiol B 2015; 153: 233–9. DOI: 10.1016/j.jphotobiol.2015.09.024
14. Ozgocmen S, Ardicoglu O, Erdogan H et al. In vivo effect of celecoxib and tenoxicam on oxidant/anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci 2005; 35 (2): 137–43.
15. Simpson J, Golding DN, Freeman AM et al. A large multicentre, parallel group, double-blind study comparing tenoxicam and piroxicam in the treatment of osteoarthritis and rheumatoid arthritis. Br J Clin Pract 1989; 43 (9): 328–33.
16. Moser U, Waldburger H, Schwarz HA, Gobelet CA. A double-blindrandomisedmulticentre study with tenoxicam, piroxicam and diclofenac sodium retard in the treatment of ambulant patients with osteoarthritis and extra-articular rheumatism. Scand J Rheumatol Suppl 1989; 80: 71–80.
17. Ejstrup L, Knudsen JV, Petersen L. A randomised double-blind multicentre trial comparing tenoxicam and ketoprofen in osteoarthritis. Scand J Rheumatol Suppl 1989; 80: 48–53.
18. Bellamy N, Buchanan WW, Chalmers A et al. A multicenter study of tenoxicam and diclofenac in patients with osteoarthritis of the knee. J Rheumatol 1993; 20 (6): 999–1004.
19. Riedemann PJ, Bersinic S, Cuddy LJ et al. A study to determine the efficacy and safety of tenoxicam versus piroxicam, diclofenac and indomethacin in patients with osteoarthritis: a meta-analysis. J Rheumatol 1993; 20 (12): 2095–103.
20. Langdon CG, Moran DG, Jamieson V et al. A multicentre study of tenoxicam for the treatment of osteo-arthritis and rheumatoid arthritis in general practice. J Int Med Res 1990; 18 (6): 489–96.
21. Kraag GR, Gordon DA, Ménard HA et al. Patient compliance with tenoxicam in family practice. Clin Ther 1994; 16 (3): 581–93.
22. Marcolongo R, Fioravanti A. Clinical experiences with tenoxicam. Preliminary results of a multicenter study. Recent Prog Med 1991; 82 (4): 242–9.
23. Ibrahima K, Kodjo G, Issa S et al. Clinical efficacy and tolerability of tenoxicam in African patients with osteoarthritis, rheumatoid arthritis, tendinitis and/or bursitis: an open study. Curr Med Res Opin 1991; 12 (7): 471–8.
24. Nived O, Sturfelt G, Eckernäs SA, Singer P. A comparison of 6 months' compliance of patients with rheumatoid arthritis treated with tenoxicam and naproxen. Use of patient computer data to assess response to treatment. J Rheumatol 1994; 21 (8): 1537–41.
25. Lund B, Andersen RB, Fossgreen J et al. A long-term randomised trial on tenoxicam and piroxicam in osteoarthritis of the hip or knee: a 24-month interim report focusing on the 12–24 month interval. Eur J Rheumatol Inflamm 1987; 9 (2): 58–67.
26. Lalos J, Tsachalos P, Gallis L. Long-term (four year) clinical trial with tenoxicam and basis therapy in patients suffering from rheumatoid arthritis. Scand J Rheumatol Suppl 1989; 80: 67–70.
27. Perez-Ruiz F, Alonso-Ruiz A, Ansoleaga JJ. Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. Clin Rheumatol 1996; 15 (5): 473–7.
28. Villa Alcázar LF, de Buergo M, Rico Lenza H, Montull Fruitós E. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. J Rheumatol 1996; 23 (7): 1194–9.
29. Valdés EF. Use of tenoxicam in patients with acute gouty arthritis. Eur J Rheumatol Inflamm 1987; 9 (2): 133–6.
30. Waterworth RF, Waterworth SM. An open assessment of tenoxicam (Tilcotil) in the treatment of acute gout in general practice. N Z Med J 1987; 100 (837): 744–5.
31. Van Durme CM, Wechalekar MD, Buchbinder R et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 2014; 9: CD010120. DOI: 10.1002/14651858.CD010120.pub2
32. Szpalski M, Hayez JP. Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain. A double-blind placebo-controlled study. Br J Rheumatol 1994; 33 (1): 74–8.
33. Cheung LK, Rodrigo C. Tenoxicam for pain relief following third molar surgery. Anesth Pain Control Dent 1992; 1 (4): 229–33.
34. Zacharias M, De Silva RK, Herbison P, Templer P. A randomized crossover trial of tenoxicam compared with rofecoxib for postoperative dental pain control. Anaesth Intensive Care 2004; 32 (6): 770–4.
35. Arslan H, Topcuoglu HS, Aladag H. Effectiveness of tenoxicam and ibuprofen for pain prevention following endodontic therapy in comparison to placebo: a randomized double-blind clinical trial. J Oral Sci 2011; 53 (2): 157–61.
36. Ilhan O, Agacayak KS, Gulsun B et al. A comparison of the effects of methylprednisolone and tenoxicam on pain, edema, and trismus after impacted lower third molar extraction. Med Sci Monit 2014; 20: 147–52. DOI: 10.12659/MSM.890239
37. Merry AF, Swinburn PF, Middleton NG et al. Tenoxicam and paracetamol-codeine combination after oral surgery: a prospective, randomized, double-blind, placebo-controlled study. Br J Anaesth 1998; 81 (6): 875–80.
38. Roelofse JA, Van der Bijl P, Joubert JJ. Analgesic and anti-inflammatory efficacy of tenoxicam and diclofenac sodium after third molar surgery. Anesth Prog 1996; 43 (4): 103–7.
39. Çebi AT, Kasapoğlu MB, Eren S, Kasapoğlu Ç. Comparison of the effects of diclofenac potassium and tenoxicam on postoperative pain, swelling, and trismus following third molar surgery. Turk J Med Sci 2018; 48 (2): 271–8. DOI: 10.3906/sag-1702-100
40. Kaplan V, Eroğlu CN. Comparison of the Effects of Daily Single-Dose Use of Flurbiprofen, Diclofenac Sodium, and Tenoxicam on Postoperative Pain, Swelling, and Trismus: A Randomized Double-Blind Study. J Oral Maxillofac Surg 2016; 74 (10): 1946.e1–6. DOI: 10.1016/j.joms.2016.05.015
41. Cevik E, Cinar O, Salman N et al. Comparing the efficacy of intravenous tenoxicam, lornoxicam, and dexketoprofen trometamol for the treatment of renal colic. Am J Emerg Med 2012; 30 (8): 1486–90. DOI: 10.1016/j.ajem.2011.12.010
42. Kekeç Z, Yilmaz U, Sözüer E. The effectiveness of tenoxicam vs isosorbide dinitrate plus tenoxicam in the treatment of acute renal colic. BJU Int 2000; 85 (7): 783–5.
43. Al-Waili NS, Saloom KY. Intravenous tenoxicam to treat acute renal colic: comparison with buscopancompositum. J Pak Med Assoc 1998; 48 (12): 370–2.
44. Al-Waili NS. Intramuscular tenoxicam to treat acute renal colic. Br J Urol 1996; 77 (1): 15–6.
45. Masudi T, Capitelli-McMahon H, Anwar S. Acute pain management in symptomatic cholelithiasis. World J Gastrointest Surg 2016; 8 (10): 713–8.
46. Chang WK, Wu HL, Yang CS et al. Effect on pain relief and inflammatory response following addition of tenoxicam to intravenous patient-controlled morphine analgesia: a double-blind, randomized, controlled study in patients undergoing spine fusion surgery. Pain Med 2013; 14 (5): 736–48. DOI: 10.1111/pme.12067
47. Gunusen I, Karaman S, Acar A et al. The efficacy of paracetamol versus tenoxicam on postoperative pain and morphine consumption after abdominal hysterectomy: a placebo-controlled, randomized study. Clin Exp Obstet Gynecol 2012; 39 (1): 49–52.
48. Munro FJ, Young SJ, Broome IJ et al. Intravenous tenoxicam for analgesia following laparoscopic cholecystectomy. Anaesth Intensive Care 1998; 26 (1): 56–60.
49. Akca T, Colak T, Kanik A et al. The effect of preoperative intravenous use of tenoxicam: a prospective, double-blind, placebo-controlled study. J Invest Surg 2004; 17 (6): 333–8.
50. Merry AF, Sidebotham DA, Middleton NG et al. Tenoxicam 20 mg or 40 mg after thoracotomy: a prospective, randomized, double-blind, placebo-controlled study. Anaesth Intensive Care 2002; 30 (2): 160–6.
51. Papathanassiou NP. Intra-articular use of tenoxicam in degenerative osteoarthritis of the knee joint. J Int Med Res 1994; 22 (6): 332–7.
52. Unlu Z, Ay K, Tuzun C. Comparison of intra-articular tenoxicam and oral tenoxicam for pain and physical functioning in osteoarthritis of the knee. Clin Rheumatol 2006; 25 (1): 54–61.
53. Erbas M, Simsek T, Kiraz HA et al. Comparison of the effectivity of oral and intra-articular administration of tenoxicam in patients with knee osteoarthritis. Braz J Anesthesiol 2015; 65 (5): 333–7. DOI: 10.1016/j.bjane.2013.12.003
54. Çift H, Özkan FÜ, Tolu S et al. Comparison of subacromial tenoxicam and steroid injections in the treatment of impingement syndrome. Eklem Hastalik Cerrahisi 2015; 26 (1): 16–20. DOI: 10.5606/ehc.2015.05
55. Guner S, Onder H, Guner SI et al. Effectiveness of local tenoxicam versus corticosteroid injection for plantar fasciitis treatment. Orthopedics 2013; 36 (10): e1322–6. DOI: 10.3928/01477447-20130920-27
56. Cook TM, Tuckey JP, Nolan JP. Analgesia after day-case knee arthroscopy: double-blind study of intra-articular tenoxicam, intra-articular bupivacaine and placebo. Br J Anaesth 1997; 78 (2): 163–8.
57. Talu GK, Ozyalçin S, Koltka K et al. Comparison of efficacy of intraarticular application of tenoxicam, bupivacaine and tenoxicam: bupivacaine combination in arthroscopic knee surgery. Knee Surg Sports Traumatol Arthrosc 2002; 10 (6): 355–60.
58. Oral EG, Hanci A, Ulufer Sivrikaya G et al. The Analgesic Effects of Morphine and Tramadol Added to Intra-articular Levobupivacaine-Tenoxicam Combination for Arthroscopic Knee Surgery on Postoperative Pain; a Randomized Clinical Trial. Anesth Pain Med 2015; 5 (3): e24047. DOI: 10.5812/aapm.5(3)2015.24047
59. Jawish R, Najdi H, Abi Safi C, Chameseddine A. The effect of intra-articular Tenoxicam on knee effusion after arthroscopy. Int Orthop 2015; 39 (7): 1423–6. DOI: 10.1007/s00264-014-2640-3
60. Sanel S, Arpaz O, Unay K et al. Comparison of intra-articular bupivacaine-morphine with bupivacaine-tenoxicam combinations on post-operative analgesia in patients with arthroscopic meniscectomy: a prospective, randomised study. Int Orthop 2016; 40 (3): 601–5. DOI: 10.1007/s00264-015-2990-5
61. Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35 (12): 1127–46. DOI: 10.2165/11633470-000000000-00000
62. Müller P, Dammann HG, Marinis E, Simon B. Gastroduodenal tolerance of tenoxicam versus diclofenac-Na: an endoscopy double-blind controlled study in healthy probands. Z Rheumatol 1989; 48 (5): 243–5.
63. Al-Quorain AA, Satti MB, Marwah S et al. Non-steroidal anti-inflammatory drug-induced gastropathy: a comparative endoscopic and histopathological evaluation of the effects of tenoxicam and diclofenac. J Int Med Res 1993; 21 (2): 89–97.
64. Perpignano G, Bogliolo A, Puccetti L. Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee. Int J Clin Pharmacol Res 1994; 14 (5–6): 203–16.
65. Lapeyre-Mestre M, Grolleau S, Montastruc JL. Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002–2006. Fundam Clin Pharmacol 2013; 27 (2): 223–30. DOI: 10.1111/j.1472-8206.2011.00991.x
66. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296 (13): 1633–44.
67. Varas-Lorenzo С, Riera-Guardia N, Calingaert B et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiology Drug Safety 2013; 22: 559–70.
68. Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology 2015; 23 (1): 1–16.
69. Arfè A, Scotti L, Varas-Lorenzo C et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016; 354: i4857. DOI: 10.1136/bmj.i4857
70. Karateev A.E. Tenoksikam. Klin. farmakologiia i terapiia. 2017; 26 (5): 44–50. [in Russian]

А.Е.Каратеев

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А.Насоновой». 115522, Россия, Москва, Каширское ш., д. 34А
aekarat@yandex.ru

________________________________________________

A.E.Karateev

V.A.Nasonova Research Institute of Rheumatology. 115522, Russian Federation, Moscow, Kashirskoe sh., d. 34A
aekarat@yandex.ru